Specific crystalline polymorphs of Compound I improve solubility and physical stability, enabling more reliable HCV protease inhibitor formulations.
A PEG-modified SN38 linker avoids heavy metal residues and improves ADC intermediate stability, safety, and tumor-site drug release.